Regulatory Affairs, SaMD & Digital Health Expert
I like to write about people, the places they live and the things with which they choose to surround themselves. Here are some of my favorite pieces that made it into Article.
The Future of Personalized Gene Editing: Hope on the Horizon In the world of medical advancements, personalized gene editing is making waves, particularly for children battling rare genetic conditions. Recently, a significant milestone was achieved when a gene editor was designed and used for a baby boy, effectively addressing his severe genetic disorder. This story, …
A New Era in Medicine: Personalized Gene-Editing Treatments The Food and Drug Administration (FDA) is taking significant steps towards making personalized gene-editing treatments a reality. Recently, top officials laid out a pathway for the approval of these groundbreaking therapies, bringing hope to many facing severe genetic disorders. Key Takeaways The FDA is paving the way …
Key Takeaways The FDA is facing challenges in appointing a new leader for its drug center after a sudden departure. Richard Pazdur and Mary Thanh Hai have both declined the role. Deputy FDA Commissioner Sara Brenner has opened the search for candidates within the agency. The FDA’s Search for Leadership The Food and Drug Administration …
Key Takeaways: A recent listeria outbreak has resulted in six deaths and over 20 illnesses linked to prepackaged pasta meals. The fragmented food safety system impedes effective outbreak investigations, leaving gaps in accountability. Establishing an independent national foodborne outbreak investigation board could enhance transparency and improve responses to such outbreaks. Understanding the Food Safety Crisis …
FDA Under Fire: A Deep Dive into Recent Tumult Last Friday, George Tidmarsh, a top official at the Food and Drug Administration (FDA), found himself in an unexpected situation. Instead of a casual update on FDA operations, he was called into Commissioner Marty Makary’s office for a surprise meeting. Tidmarsh had his suspicions. He thought …
Rising Tensions at the FDA: A Look into the Center for Biologics Evaluation and Research Recent tensions at the Food and Drug Administration (FDA) have put the future of the Center for Biologics Evaluation and Research (CBER) in jeopardy. Vinay Prasad, the center’s director, is at the center of a growing controversy that has led …
Exploring the Buzz in Biopharma: What You Need to Know The biopharmaceutical industry is buzzing, especially in places like North Carolina. If you want to keep up with the latest developments, understand how this sector is evolving, and find out what it all means for healthcare, you’re in the right place. Let’s break down some …
FDA’s New Priority Review Voucher Program: What You Need to Know The Food and Drug Administration (FDA) is revamping how it reviews drugs, and Commissioner Marty Makary wants to speed things up. One of the latest initiatives is a new priority review voucher program launched in June. This program is all about finding innovative ways …
Telehealth Boom: Exploring the Benefits and Challenges TL;DR: The COVID-19 pandemic accelerated the adoption of telehealth, bringing numerous benefits such as increased accessibility, convenience, and cost-effectiveness. However, it also presents challenges including privacy concerns, technology access disparities, and the need for quality assurance. Understanding these aspects is crucial for anyone interested in the evolving landscape …
Key Takeaways: The FDA is experiencing significant changes affecting drug approvals. Drug approval rates have dropped from 87% to 73% in the last quarter. Rejections of marketing applications surged to 15%, higher than the typical 10%. Review delays for applications increased to 11%, compared to an average of 4%. The recent shake-up at the Food …